In a clinical study conducted in 2020, pembrolizumab, an anti-PD-1 agent, exhibited significant improvements in PFS (16.5 vs. 8.2 months) compared to standard treatments as a first-line therapy for metastatic MSI-H colon cancer patients (156). This evidence concerns the gene PDCD1 and colonic neoplasm.